Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Press Releases

Press Releases

  • Oct 09, 2018
    Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases
    Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290                Initial development candidate expected in H2 2019 CAMBRIDGE, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering
  • May 31, 2018
    Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

    CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , M.D., MBA, President and Chief Executive





  • Events and Presentation